A study on thromboembolism of patients with pancreatic cancer.

Authors

null

Kwan Yu LAM

Prince of Wales Hospital, Hong Kong, Hong Kong, Hong Kong

Kwan Yu LAM , Kirsty Lee , Charing Chong , Anthony WH Chan , Tony Mok , Stephen Lam Chan

Organizations

Prince of Wales Hospital, Hong Kong, Hong Kong, Hong Kong, PRINCE OF WALES HOSPITAL, Hong Kong, Hong Kong, The Chinese University of Hong Kong, Hong Kong, Hong Kong, Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China

Research Funding

Other

Background: There have been studies on the association between thromboembolism (TE) and pancreatic cancer in Caucasian patients. This study aims to study the TE in Chinese patients with pancreatic cancer. Methods: This study retrospectively reviewed consecutive patients with confirmed diagnoses of pancreatic cancers from 2010-2015 in the Prince of Wales Hospital in Hong Kong. Patients with radiologically confirmed TE were identified. Corresponding information related to the type and site of TE were recorded. Predictive factors for the TE were studied by multivariate analysis. Results: Total 372 patients with pancreatic cancer were identified. In the cohort, the diagnoses of cancers were made by histology in 225 (60.5%) of them while others were made by radiology. The stage was as follows: 15 (4.1%) stage I; 113 (30.4%) stage II; 47 (12.7%) stage III and 196 (52.7%) stage IV. Total 55 (14.7%) patients had TE after diagnosis of pancreatic cancer. Of these 55 patients, 33 (60%) and 18 (32.7%) had venous and arterial events, respectively. For patients with TE, 27 (49.1%) were treated with anti-coagulants, and 13 (23.6%) had surgery within 2 years. The median time from surgery to the development of TE was 1.06 years. Patients with ECOG ≥2 and metastatic disease (HR 2.92, 95% CI 1.58-5.37; HR 6.90, 95% CI 3.63-13.14 respectively) had a higher risk of developing TE. Patients with venous, arterial, or both types of TE did not have significantly different overall survival. Poor prognostic factors for overall survival include ECOG ≥2 (HR 2.80, 95% CI 2.18-3.60) and tumour stage (stage II disease HR 1.36, 95% CI 0.70-2.62; stage III disease HR 1.85, 95% CI 0.92-3.70; stage IV disease HR 4.92, 95% CI 2.58-9.36). The presence of TE equated to a worse overall survival (median overall survival 148 vs. 228 days, HR 1.03, 95% CI 0.75-1.40, P=0.87), which was statistically insignificant. Conclusions: TE was similarly high in Chinese patients with pancreatic cancer. Patients with poorer performance status and metastatic disease had a greater risk of developing TE. Patients with TE had a worse overall survival (which was statistically insignificant) compared to patients without TE.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Prevention, Diagnosis, and Screening

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 262)

DOI

10.1200/JCO.2017.35.4_suppl.262

Abstract #

262

Poster Bd #

B18

Abstract Disclosures

Similar Abstracts

First Author: JEONGSEOK JEON

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Overall survival (OS) in gastrointestinal (GI) neuroendocrine tumors (NETs) based on primary site, stage, and surgery.

First Author: Bahar Laderian

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Factors associated with the receipt of surgery in acinar cell carcinoma of the pancreas.

First Author: Jasleen Kaur Chaddha